Hinova PharmaceuticalsSHSE:688302 +2.12%24 Days Payable is 174,796.17 as of Mar. 2026, which is 325% above its 10-year median of 41,161.72. GuruFocus rates SHSE:688302 with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 701 Biotechnology companies, Hinova Pharmaceuticals ranks better than 98.86% on this metric.
The historical rank and industry rank for Hinova Pharmaceuticals's Days Payable or its related term are showing as below:
SHSE:688302'
s Days Payable Range Over the Past 10 Years
Min: 21451.33 Med: 41161.72 Max: 141990.16
Current: 110609.34
During the past 8 years, Hinova Pharmaceuticals's highest Days Payable was 141990.16. The lowest was 21451.33. And the median was 41161.72.
SHSE:688302's Days Payable is ranked better than 98.86% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs SHSE:688302: 110609.34
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688302 vs VRTX, REGN, ALNY: Days Payable Comparison
For the Biotechnology subindustry, Hinova Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hinova Pharmaceuticals Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hinova Pharmaceuticals's Days Payable distribution charts can be found below:
* The bar in red indicates where Hinova Pharmaceuticals's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Hinova Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hinova Pharmaceuticals (SHSE:688302) has a Days Payable of 174,796.17 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hinova Pharmaceuticals and its competitors. This is 325% above median its historical median of 41,161.72. Over the past decade, Hinova Pharmaceuticals' Days Payable has ranged from 21,451.33 to 141,990.16. According to the industry distribution chart, Hinova Pharmaceuticals ranks #8 out of 701 companies in the Biotechnology industry, placing it in the top 1.1%.
Is Hinova Pharmaceuticals' Days Payable too high?
Hinova Pharmaceuticals' current Days Payable of 174,796.17 is 325% above median its 10-year median of 41,161.72. Over the past 10 years, this metric has ranged from a low of 21,451.33 to a high of 141,990.16. The Biotechnology industry median Days Payable is 112.84. Hinova Pharmaceuticals' value of 174,796.17 is 154806.2% above this industry median. Based on the distribution chart, Hinova Pharmaceuticals ranks #8 out of 701 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Hinova Pharmaceuticals has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Hinova Pharmaceuticals' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hinova Pharmaceuticals ranks #8 out of 701 companies for Days Payable. This places Hinova Pharmaceuticals in the top 1% of its industry — outperforming the majority of peers. The industry median Days Payable is 112.84. Hinova Pharmaceuticals' value of 174,796.17 is 154806.2% above this benchmark. Historically, Hinova Pharmaceuticals' own Days Payable has ranged from 21,451.33 to 141,990.16 over the past decade. While the company's 10-year median is 41,161.72 vs. the industry median of 112.84, Hinova Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hinova Pharmaceuticals's current Days Payable of 174,796.17 is 154806.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Hinova Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hinova Pharmaceuticals's current Days Payable is 174,796.17, which is 325% above median its own 10-year median of 41,161.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hinova Pharmaceuticals stock overvalued right now?
Hinova Pharmaceuticals (SHSE:688302) has a current Days Payable of 174,796.17. The current Days Payable is 174,796.17, which is 325% above median its 10-year median of 41,161.72 and 154806.2% above the Biotechnology industry median of 112.84. Hinova Pharmaceuticals' overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Hinova Pharmaceuticals (SHSE:688302), the current Days Payable is 174,796.17 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Hinova Pharmaceuticals Inc is an international drug company based on technology platforms such as deuterium and PROTAC, aiming to develop Best-in-class and First-in-class drugs with major clinical needs. The company focuses on the research and development of drugs in therapeutic areas such as oncology and metabolic diseases, focusing on providing safe, effective and affordable drugs for patients, and is committed to the development and production of drugs with global rights and interests.
24GF Score
Get the complete analysis for SHSE:688302
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688302 has been successfully added to your 
